ETNB - NASDAQ

89bio, Inc.

ETNB·NASDAQ

$14.84

+0.0000%

HealthcareBiotechnology

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$2.20B

EPS-3.5100

P/E Ratio-2.23

Earnings Date11/06/2025

etnb

Accumulated Other Comprehensive Income (Loss)

Last Annual Value

563.00K

3-Year CAGR

121%

5-Year CAGR

15%

10-Year CAGR

58%

Adjust for Inflation

89bio, Inc. Competitors Analysis of Accumulated Other Comprehensive Income (Loss)

ETNB · NASDAQ

Company	Accumulated Other Comprehensive Income (Loss)	CAGR 3Y	CAGR 5Y	CAGR 10Y
89bio, Inc. NASDAQ:ETNB	563.00K	43.6%	N/A	N/A
Agios Pharmaceuticals, Inc. NASDAQ:AGIO	2.19M	N/A	N/A	N/A
Beam Therapeutics Inc. NASDAQ:BEAM	1.11M	22.5%	N/A	N/A
Cogent Biosciences, Inc. NASDAQ:COGT	355.00K	13.0%	N/A	N/A
Denali Therapeutics Inc. NASDAQ:DNLI	682.00K	2.0%	N/A	N/A
ImmunityBio, Inc. NASDAQ:IBRX	28.96M	1325.3%	491.5%	N/A
Liquidia Corporation NASDAQ:LQDA	0.00	N/A	N/A	N/A
Ocular Therapeutix, Inc. NASDAQ:OCUL	0.00	N/A	N/A	N/A
Arcus Biosciences, Inc. NYSE:RCUS	0.00	N/A	N/A	N/A
Recursion Pharmaceuticals, Inc. NASDAQ:RXRX	36.72M	N/A	N/A	N/A

89bio, Inc. Fair Value Envelope

ETNB · NASDAQ

Our analysis suggests that ETNB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $14.84, this represents a potential HIDDEN relative to our calculated worth for 89bio, Inc..

HIDDEN

Intrinsic Value

Current Price: $14.84

Related Guides

Blog Categories

Continue your ETNB research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.